My watch list

Vernalis

Vernalis plc (LSE:VER.L Nasdaq:VNLS)
	Public
Founded	2003 from merger
Headquarters	Winnersh, United Kingdom
Key people	CEO Robert Mansfield, 1992-2003 Simon Sturge, 2003- Chair George Kennedy, 2000-2003 Peter Fellner, 2003-
Industry	Biotechnology
Products	Frovatriptan, Apokyn
Employees	200
Website	Vernalis

Vernalis Plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.^[1] The merger allowed British Biotech to ditch its historic but tarnished name.^[2]

Additional recommended knowledge

What is the Correct Way to Check Repeatability in Balances?

Essential Laboratory Skills Guide

Safe Weighing Range Ensures Accurate Results

The company has marketed two drug products; Frovatriptan,,^[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.^[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono.

References

^ Vernalis agrees £91m merger plan with British Biotech. Advances in Life Science. ALS (2003). Retrieved on 2003-07-03.
^ Fifth Report. Select Committee on Science and Technology. House of Commons (1998). Retrieved on 2007-11-28.
^ Patient Information Sheet -- Frovatriptan succinate (marketed as Frova). Food and Drug Administration (07/2006). Retrieved on 2007-11-28.
^ Apokyn. FDA (2004). Retrieved on 2004-07-29.